| 1 |
34951582 | 5-Fluorouracil-Impregnated PLGA Coated Gold Nanoparticles for Augmented Delivery to Lung Cancer: In Vitro Investigations. | 2022 |
1 |
| 2 |
35445157 | Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells. | 2022 Apr |
5 |
| 3 |
32990544 | Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects via Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells. | 2021 |
1 |
| 4 |
34360807 | Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer. | 2021 Jul 27 |
1 |
| 5 |
32062671 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. | 2020 Feb 16 |
1 |
| 6 |
32814111 | In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. | 2020 Dec |
2 |
| 7 |
32879665 | Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer. | 2020 Aug 15 |
1 |
| 8 |
33120790 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. | 2020 Oct 23 |
1 |
| 9 |
30307354 | Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. | 2019 |
1 |
| 10 |
30579838 | Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. | 2019 Feb |
2 |
| 11 |
31010234 | Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. | 2019 Apr 19 |
2 |
| 12 |
31126331 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. | 2019 May 24 |
1 |
| 13 |
29508026 | A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. | 2018 May |
1 |
| 14 |
30188916 | Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. | 2018 |
2 |
| 15 |
28551618 | MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. | 2017 Jun |
1 |
| 16 |
27144434 | MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. | 2016 Jun 7 |
1 |
| 17 |
28101205 | Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. | 2016 Dec |
1 |
| 18 |
24889488 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. | 2015 Jan |
1 |
| 19 |
25325304 | Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line. | 2015 Feb |
3 |
| 20 |
25605843 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Mar 1 |
1 |
| 21 |
25870609 | Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. | 2015 |
1 |
| 22 |
25919696 | MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. | 2015 Apr 28 |
1 |
| 23 |
25937522 | FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Jul |
1 |
| 24 |
26130327 | 5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. | 2015 Nov |
3 |
| 25 |
24692733 | Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. | 2014 Apr |
2 |
| 26 |
24764659 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. | 2014 Apr 21 |
1 |
| 27 |
25209093 | Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. | 2014 Sep |
2 |
| 28 |
25216706 | Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity. | 2014 Oct |
1 |
| 29 |
23555026 | The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. | 2013 |
1 |
| 30 |
23689915 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. | 2013 Jul |
1 |
| 31 |
23730514 | Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. | 2013 Jun |
2 |
| 32 |
23822592 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. | 2013 Oct |
1 |
| 33 |
24211581 | The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells. | 2013 Nov 29 |
1 |
| 34 |
22740893 | Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation. | 2012 Feb |
1 |
| 35 |
20972872 | Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. | 2011 Aug |
1 |
| 36 |
21228335 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. | 2011 Jul |
1 |
| 37 |
21635994 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. | 2011 Apr |
2 |
| 38 |
21855038 | An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. | 2011 Sep |
1 |
| 39 |
20354524 | Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. | 2010 Apr 13 |
3 |
| 40 |
20740189 | Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases. | 2010 May 7 |
1 |
| 41 |
22811812 | KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. | 2010 Dec |
1 |
| 42 |
12827409 | Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. | 2004 Jan |
1 |
| 43 |
11745689 | Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. | 2001 Dec |
1 |
| 44 |
9515799 | Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. | 1998 Mar 15 |
2 |
| 45 |
9327152 | Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292) | 1997 Sep-Oct |
2 |
| 46 |
9345343 | Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). | 1997 Oct |
3 |
| 47 |
9816002 | Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival | 1995 Apr |
2 |